Research & Development

Billion-Dollar Deals Drive Innovation in Oncology Research and Development
Research & Development Billion-Dollar Deals Drive Innovation in Oncology Research and Development

The landscape of biopharmaceutical research and development (R&D) has seen a remarkable evolution, particularly in the realm of oncology. In recent years, a significant portion of R&D investments has been channeled into cancer research, paving the way for groundbreaking treatments and therapies.

Recursion Confirms Safety of Experimental Drug REC-994, Efficacy Uncertain
Research & Development Recursion Confirms Safety of Experimental Drug REC-994, Efficacy Uncertain

Recursion Pharmaceuticals has reached a significant milestone in its journey to develop a treatment for cerebral cavernous malformation (CCM), a complex neurovascular condition. The company's leading experimental drug, REC-994, recently concluded a Phase 2 clinical trial, and the results are both

Can Expanded Clinical Sites Enhance AL Amyloidosis Treatment Access?
Research & Development Can Expanded Clinical Sites Enhance AL Amyloidosis Treatment Access?

The advancement in biopharmaceutical research holds promise for patients with rare conditions such as relapsed/refractory AL amyloidosis. Immix Biopharma, Inc. (IMMIX), aims to tackle this debilitating disease through its innovative CAR-T cell therapy, NXC-201. As of August 28, 2024, the company

Immix Biopharma Expands NEXICART-2 Trial for AL Amyloidosis Treatment
Research & Development Immix Biopharma Expands NEXICART-2 Trial for AL Amyloidosis Treatment

Immix Biopharma, Inc. (Nasdaq: IMMX) recently announced a significant expansion of its clinical trial sites across the United States for the NEXICART-2 study, focusing on relapsed/refractory AL Amyloidosis. This expansion aims to provide broader patient access to innovative therapy options and

Genentech Layoffs and Restructuring: Impacting Key South San Francisco Roles
Research & Development Genentech Layoffs and Restructuring: Impacting Key South San Francisco Roles

Genentech, a prominent subsidiary of Roche, is undergoing significant layoffs and restructuring efforts, which are slated to impact various roles at its South San Francisco operations. This development follows a recent announcement that 93 employees will be laid off starting in early October. The

Are U.S. Clinical Trials in China Facing More FDA Scrutiny?
Research & Development Are U.S. Clinical Trials in China Facing More FDA Scrutiny?

U.S. lawmakers are raising alarms about clinical trials conducted in China, specifically those affiliated with the Chinese military or located in the Xinjiang Uyghur Autonomous Region. This heightened vigilance is poised to dramatically impact how the U.S. FDA scrutinizes data from these trials.

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later